HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of special pharmaceuticals, primarily in the high-priced indication areas of oncology and HIV as well as rheumatism, neurology and cardiovascular diseases. HAEMATO AG had a successful second half of 2017. The first products developed in-house in the field of aesthetic applications were delivered in December 2017. HAEMATO AG sees this as an additional business field in an attractive market environment that will strengthen the basis for further growth and additional earnings.

The annual report published today for the reporting period from January 1, 2017 to December 31, 2017 is available for download.